Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

ABSTRACT: Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

PROVIDER: PRJNA963056 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24350100_1.fastq.gz	Fastqsanger.gz
	SRR24350100_2.fastq.gz	Fastqsanger.gz
	SRR24350200_1.fastq.gz	Fastqsanger.gz
	SRR24350200_2.fastq.gz	Fastqsanger.gz
	SRR24350300_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 604

Similar Datasets

Plasma cell-free DNA hydroxymethylomes define disease state in EGFR-mutant non-small cell lung cancer

Project description:The epigenome of plasma cell-free DNA (cfDNA) has demonstrated promise as both a prognostic and predictive cancer biomarker in liquid biopsies. Currently, it remains unknown whether and why cfDNA 5-hydroxymethylcytosine (5hmC) can identify disease state for non-small cell lung cancer (NSCLC). We profiled 5-hydroxymethylomes using the plasma cfDNA of 302 EGFR-mutant NSCLC patients with different disease states. We found NSCLCs were epigenetically heterogeneous among individuals, especially for cfDNA 5hmC on gene EGFR. The diversity of age, sex, race, smoking status, EGFR-mutation of patients increased the epigenetic heterogeneity of NSCLC, however, only smoking status shaped disease state-associated cfDNA 5hmC. More importantly, disease state-dependent and patients’ characteristics-independent cfDNA 5hmC can be linked to lung function and regulatory elements in human lung cells. Interestingly, although 5-hydroxymethylome heterogeneity of plasma cfDNA among NSCLC patients were detected substantially, cfDNA-5hmC-based machine learning model can accurately predict different disease state in NSCLC.

2025-01-29 | GSE231296 | GEO

Epigenomics of Prostate Cancer from Cell Free Plasma

Project description:Epigenomics of Prostate Cancer from Cell Free Plasma

| PRJNA1047253 | ENA

Epigenomics of Prostate Cancer from Cell Free Plasma

Project description:Epigenomics of Prostate Cancer from Cell Free Plasma

| PRJNA1047258 | ENA

Cell-Free Plasma MicroRNAs that Identify Patients with Glioblastoma

Project description:Cell-Free Plasma MicroRNAs that Identify Patients with Glioblastoma

| PRJNA764727 | ENA

Repeat-element-aware profiling of plasma cell-free RNA

Project description:Repeat-element-aware profiling of plasma cell-free RNA

| PRJNA562932 | ENA

Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

Project description:Subtyping of Small Cell Lung Cancer using plasma cell-free nucleosomes

| PRJNA1006798 | ENA

Fragmentomic features of seminal plasma cell-free DNA revealed by low-coverage whole-genome sequencing in male infertility

Project description:Seminal plasma cell-free DNA

| PRJEB98078 | ENA

Plasma Cell-free RNA Signatures of Inflammatory Syndromes in Children

Project description:Plasma Cell-free RNA Signatures of Inflammatory Syndromes in Children

| PRJNA1075432 | ENA

Plasma cell-free RNA profiling distinguishes cancer from pre-malignant conditions

Project description:Cell-free RNA (cfRNA) in plasma reflects gene expression profiles of both localized sites of cancer and at the systemic host response. Here we explore the diagnostic potential of cell-free transcriptomes by mRNA sequencing. We sequenced total cell-free plasma RNA from 90 plasma samples from two independent sample cohorts representing two cancer types, two pre-cancerous conditions and non-cancer donors. We identified distinct gene sets and built classification models that could distinguish cancer patients with specific cancer types from premalignant conditions and non-cancer individuals with high accuracy. Determination of multiple myeloma from its pre-cancerous monoclonal gammopathy of undetermined significance (MGUS) yielded an accuracy of 90% (17/19). Detection of primary liver cancer from its premalignant condition cirrhosis yielded an accuracy of 100% (12/12). This work lays the foundation for developing low cost assays by measuring mRNA transcript levels in plasma using a small panel of genes for detection that can distinguish the presence of cancer from pre-cancerous conditions and non-cancer individuals.

2022-04-25 | GSE182824 | GEO

Urine Cell-Free RNA versus Plasma Cell-Free RNA for Monitoring of Immune and Urinary Tract Complications

Project description:Urine Cell-Free RNA versus Plasma Cell-Free RNA for Monitoring of Immune and Urinary Tract Complications

| PRJNA1084833 | ENA